In particular, the activation of CD8+ Teffector or CD4+ Thelper cells was shown to be suppressed by tumor-derived sEVs, e.g., upon targeting antigen-presenting dendritic cells (DC), thus impairing lymphocyte activation and survival [162]. The gene discussed is CD8A; the disease is neoplasm.